Sarepta Therapeutics Announces Proposed Public Offering of Common Stock

  Sarepta Therapeutics Announces Proposed Public Offering of Common Stock

Business Wire

CAMBRIDGE, Mass. -- April 22, 2014

Sarepta Therapeutics, Inc. (Nasdaq: SRPT), a developer of innovative RNA-based
therapeutics, today announced that it is offering to sell, subject to market
and other conditions, up to $100 million of its common stock in an
underwritten public offering. Sarepta also intends to grant the underwriters a
30-day option to purchase from it up to an additional $15 million of shares.

BofA Merrill Lynch and Morgan Stanley are acting as joint book-running
managers of the proposed offering.

Sarepta intends to use the net proceeds from the offering for business
development, manufacturing, continued development of eteplirsen and other
product candidates and general corporate purposes.

The shares are being offered by Sarepta pursuant to an automatically effective
shelf registration statement that was previously filed with the Securities and
Exchange Commission (SEC). A preliminary prospectus supplement relating to and
describing the terms of the offering will be filed with the SEC and will be
available on the SEC’s web site at When available, copies of the
preliminary prospectus supplement relating to these securities may also be
obtained from the offices of BofA Merrill Lynch, 222 Broadway, New York, NY
10038, Attn: Prospectus Department, or via email, at; or Morgan Stanley & Co. LLC at 180 Varick
Street, Second Floor, New York, New York 10014, Attention: Prospectus
Department or by emailing The final terms of the
offering will be disclosed in a final prospectus supplement to be filed with
the SEC.

This press release does not constitute an offer to sell or a solicitation of
an offer to buy any securities of Sarepta, nor shall there be any sale of
securities in any state or jurisdiction in which such an offer, solicitation
or sale would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.

AboutSarepta Therapeutics

Sarepta Therapeuticsis focused on developing first-in-class RNA-based
therapeutics to improve and save the lives of people affected by serious and
life-threatening rare and infectious diseases. The Company's diverse pipeline
includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well
as potential treatments for some of the world's most lethal infectious
diseases. Sarepta aims to build a leading, independent biotech company
dedicated to translating its RNA-based science into transformational
therapeutics for patients who face significant unmet medical needs.

Forward-Looking Statements and Information

This press release contains statements that are forward-looking, including the
statements about the completion, timing and size of the proposed public
offering of Sarepta’s common stock, within the meaning of Section27A of the
Securities Act of 1933 and Section21E of the Securities Exchange Act of 1934.
These forward-looking statements involve risks and uncertainties, many of
which are beyond Sarepta’s control, including risk and uncertainties related
to market conditions and satisfaction of customary closing conditions related
to the proposed public offering. There can be no assurance that Sarepta will
be able to complete the public offering on the anticipated terms, or at all.
Applicable risks also include those that are included in the “Risk Factors”
section of Sarepta’s Annual Report on Form 10-K for the year ended December
31, 2013, and any subsequent SEC filings, including the prospectus supplement
related to the proposed offering to be filed with the SEC. Any forward-looking
statement in this press release represents Sarepta’s views only as of the date
of this press release and should not be relied upon as representing its views
as of any subsequent date. Sarepta does not undertake any obligation to
publicly update its forward-looking statements based on events or
circumstances after the date hereof, except as required by applicable law.



Investor Contact:
Erin Cox, 617-274-4014
Media Contact:
Jim Baker, 617-274-4010
Press spacebar to pause and continue. Press esc to stop.